CroíValve is a technology company.
CroíValve has raised $31.0M across 4 funding rounds.
CroíValve has raised $31.0M in total across 4 funding rounds.
CroíValve has raised $31.0M in total across 4 funding rounds.
CroíValve's investors include Broadview Ventures, SOSV, BioStar Ventures.
CroíValve is a clinical-stage medtech company developing the DUO™ System, a minimally invasive transcatheter device for treating tricuspid regurgitation (TR), a common heart valve disorder affecting millions worldwide that leads to blood backflow and heart complications.[1][2][3][6] The device serves high-risk patients unsuitable for open-heart surgery, solving the problem of invasive, risky procedures by delivering via a neck vein catheter to restore native valve function without penetrating tissue or disrupting anatomy.[1][3][5] Backed by €8M Series A (2022) and $16M Series B funding, CroíValve—spun out from Trinity College Dublin—shows strong growth, expanding its team to 10+ with a new CTO and preparing a US feasibility study.[2][4]
Founded in 2016 as a spin-out from Trinity College Dublin's Trinity Centre for Bioengineering, CroíValve emerged from Dr. Martin Quinn's vision after pioneering Ireland's first transcatheter aortic valve replacement in 2008, inspiring solutions for tricuspid and mitral valves.[2][4][5] Co-founders include CEO Dr. Lucy O’Keeffe, with over a decade leading medtech programs at multinationals; Dr. Paul Heneghan, a PhD engineer in device design; and Prof. Bruce Murphy, head of TCD's medtech incubator.[2][4][5] Early traction came via Enterprise Ireland and EIT Health funding for R&D, evolving from concepts preserving native leaflets to the DUO™ System, with pre-clinical validation proving superior safety and efficacy.[1][2][5]
CroíValve stands out in the TR medtech space through these key advantages:
CroíValve rides the explosive growth in transcatheter heart valve repairs, targeting the €3B TR market amid rising prevalence in aging populations (over 4M cases in US/Europe alone).[1][6][7] Timing aligns with momentum from giants like Edwards Lifesciences and Abbott, whose recent TR advances highlight demand for scalable, non-surgical options, yet leave gaps in broad applicability that CroíValve exploits via its native-preserving approach.[7] Market forces—underdiagnosis, high-risk elderly patients, and regulatory progress in the US—favor minimally invasive medtech, positioning CroíValve to influence ecosystem standards by enabling wider adoption and shorter practitioner training.[2][3][4]
CroíValve's $16M Series B fuels a pivotal US feasibility study for the DUO™ System, accelerating toward broader trials and market entry in a heating TR space.[4] Trends like AI-guided imaging and personalized devices will shape its path, amplifying advantages in scalability amid competition from incumbents.[7] Its influence may evolve by redefining TR care as first-line for diverse anatomies, transforming outcomes for millions—echoing its founding mission to pioneer safer heart interventions.[2][6]
CroíValve has raised $31.0M across 4 funding rounds. Most recently, it raised $16.0M Series B in August 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2024 | $16.0M Series B | Broadview Ventures, SOSV | |
| Feb 1, 2022 | $9.0M Series A | BioStar Ventures, Broadview Ventures, SOSV | |
| Sep 1, 2019 | $2.0M Seed | BioStar Ventures, Broadview Ventures, SOSV | |
| Mar 1, 2019 | $4.0M Seed | Broadview Ventures, SOSV |